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Abstract In this study we show that both glycogen synthase
kinase 3 (GSK3) isoforms, GSK3K and GSK3L, are present in
human platelets and are phosphorylated on Ser21 and Ser9,
respectively, in platelets stimulated with collagen, convulxin
and thrombin. Phosphorylation of GSK3K/L was dependent on
phosphoinositide 3-kinase (PI3K) activity and independent of
platelet aggregation, and correlated with a decrease in GSK3
activity that was preserved by pre-incubating platelets with
PI3K inhibitor LY294002. Three structurally distinct GSK3
inhibitors, lithium, SB415286 and TDZD-8, were found to in-
hibit platelet aggregation. This implicates GSK3 as a potential
regulator of platelet function.
3 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Platelets play a pivotal role in haemostasis. Upon damage
to the vascular wall platelets are exposed to extracellular ma-
trix proteins, such as collagens, to which they adhere and
aggregate together to form an haemostatic plug. E¡ective
platelet responses are ensured through positive feedback
mechanisms, due to the activity of molecules released by acti-
vated platelets. Precise regulation of platelet function is essen-
tial to prevent inappropriate activation of platelets and the
occurrence of thrombosis.
Central to platelet activation are a number of cell surface
receptors, including the collagen receptors, glycoprotein VI
(GPVI) [1,2] and integrin K2L1 [3], the thrombin receptors,
PAR1 and PAR4 [4], and the ¢brinogen receptor, integrin
KIIbL3 [5], amongst others. The integrin K2L1 and GPVI act
in concert to support the adhesion of platelets to collagen [6].
Collagen binding to GPVI results in receptor clustering and
tyrosine phosphorylation of the Fc receptor Q-chain, an asso-
ciated transmembrane protein. This results in the recruitment
of signalling molecules leading to the activation of multiple
signalling pathways that culminate in platelet shape change,
secretion and aggregation [7,8]. Thrombin, generated at sites
of tissue damage, is also a potent platelet agonist [4].
Although collagen and thrombin activate di¡erent receptor
types, they share a number of common signalling components
including the mobilisation of calcium from intracellular stores
and the activation of phosphoinositide 3-kinase (PI3K) [9].
Despite the importance of PI3K in platelet regulation the
functionally important e¡ectors that lie downstream of
PI3K in platelets are not understood. Protein kinase B
(PKB/Akt), a known e¡ector of PI3K, is regulated by a num-
ber of platelet agonists, including collagen, thrombin and
thrombopoietin [10,11]. The potential importance of PKB in
platelet function led us to examine a known substrate in other
cell systems, glycogen synthase kinase 3 (GSK3).
GSK3 is a widely expressed cytoplasmic serine/threonine
protein kinase. It exists as two highly homologous isoforms,
GSK3K (51 kDa) and GSK3L (46 kDa), that are encoded by
two di¡erent genes but are regulated in a similar manner [12].
Originally identi¢ed as one of several protein kinases that can
phosphorylate glycogen synthase, GSK3 has become recog-
nised to play a role in the regulation of many cell functions
[12].
In this study we demonstrate the presence of both isoforms
of GSK3 in human platelets and show regulation of GSK3 in
response to a number of platelet agonists. We show that this
leads to the phosphorylation of both GSK3K and GSK3L, the
kinetics of which mirror that of the phosphorylation of PKB.
Phosphorylation of GSK3 correlates with inhibition of its en-
zymic activity, which is also PI3K dependent. Furthermore,
investigation of the e¡ects of selective GSK3 inhibitors impli-
cates GSK3 in the regulation of platelet function.
2. Materials and methods
Anti-phospho-GSK3K/L, anti-PKB and anti-phospho-PKB (Ser473)
antibodies were purchased from New England Biolabs (Hertfordshire,
UK). Anti-GSK3K and anti-GSK3L antibodies and GSK3 substrate
peptide 2 were purchased from Upstate Biotechnology (TCS Biolog-
icals, Buckingham, UK). Horseradish peroxidase-conjugated second-
ary antibodies, enhanced chemiluminescence (ECL) reagents were
from Amersham Biosciences (Buckinghamshire, UK). LY294002,
wortmannin and TDZD-8 were from Calbiochem (CN Biosciences,
Nottingham, UK), Bradford protein assay reagent was from Bio-
Rad (Hertfordshire, UK), and SB415286 was from Tocris (Bristol,
UK). All other reagents were from previously described sources
[13].
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2.1. Preparation and stimulation of platelets
Fresh human platelets were obtained from volunteers, prepared as
described previously [14] and resuspended in Tyrodes^HEPES bu¡er
(134 mM NaCl, 0.34 mM Na2HPO4, 2.9 mM KCl, 12 mM NaHCO3,
20 mM HEPES, 5 mM glucose, 1 mM MgCl2, pH 7.3) containing 10
WM indomethacin to a density of 8U108 cells/ml. Platelets (450 Wl)
were stimulated with collagen, convulxin, or thrombin at 37‡C in an
aggregometer with continuous stirring (1200 rpm). For inhibitor stud-
ies platelets were incubated with the appropriate inhibitor [dissolved
in dimethyl sulphoxide (DMSO), ¢nal concentration 6 0.2% (v/v)] for
15 min prior to stimulation. Where stimulations were performed
under non-aggregating conditions, platelets were pre-incubated for
30 min with 1 mM EGTA.
2.2. Immunoblotting
Platelet stimulation was stopped by the addition of Laemmli sample
bu¡er, proteins separated by sodium dodecyl sulfate^polyacrylamide
gel electrophoresis (SDS^PAGE) and transferred to PVDF mem-
branes by Western blotting. After blocking by incubation in Tris-bu¡-
ered saline-Tween [TBS-T; 20mM Tris, 137 mM NaCl, 0.1% (v/v)
Tween 20, pH7.6] containing 5% (w/v) milk protein, membranes
were incubated overnight at 4‡C with primary antibody (1 Wg/ml) in
TBS-T containing 5% (w/v) milk protein. Subsequent to washing in
TBS-T, membranes were incubated with horseradish peroxidase-con-
jugated secondary antibody (0.1 Wg/ml) in 5% (w/v) milk protein in
TBS-T, and then washed with TBS-T. Membranes were incubated
with ECL substrate reagent and exposed to X-ray ¢lm.
2.3. Immunoprecipitation
Cells were lysed using an equal volume of RIPA bu¡er [200 mM
NaCl, 62.5 WM Na deoxycholate, 50 mM Tris, 0.5% (w/v) SDS, 0.5%
(v/v) Nonidet P40, pH 7.4 containing 1 Wg/ml pepstatin A, 10 Wg/ml
leupeptin, 10 Wg/ml aprotinin, 1 mM phenylmethylsulphonyl £uoride
(PMSF), 10 WM okadaic acid and 2 mM Na3VO4] and incubated on
ice for 15 min. Clari¢ed supernatants were pre-cleared by incubation
with protein A Sepharose [PAS; 20 Wl of a 50% (v/v) suspension in
TBS-T] for 30 min. Following removal of the PAS, 1 Wg of the ap-
propriate antibody was added to each sample and incubated for 1 h
before the addition of 40 Wl PAS. After a 1 h incubation PAS beads
were washed three times in TBS-T, and Laemmli sample bu¡er added.
2.4. GSK3 kinase assay
GSK3 activity was measured in platelet lysates using the method
described by Ryves et al. [15]. Platelets were stimulated for 5 min in
the presence or absence of LY294002. The reaction was stopped by
the addition of ice-cold lysis bu¡er [50 mM Tris^HCl (pH 7.5), 150
mM NaCl, 5 mM EDTA, 50 mM NaF, 1% (v/v) Triton X-100, con-
taining 10 WM dithiothreitol (DTT), 100 nM okadaic acid, 0.5 mM
Na3VO4, 1 mM benzamidine, 1 mM PMSF, 1Wg/ml pepstatin and
1 Wg/ml leupeptin]. Protein concentrations were determined using
the Bradford microassay, and 10 Wg of protein used for each kinase
assay. To a duplicate set of samples 50 mM LiCl was added. Sub-
sequently, 40 WM substrate peptide (derived from glycogen synthase;
YRRAAVPPSPSLSRHSSPHQpSEDEEE) was added to each tube
and the reaction started by addition of 3 WCi [32P]ATP in kinase
bu¡er [50 mM Tris^HCl (pH 7.5), 100 WM ATP, 12.5 mM MgCl2,
0.5 mM EGTA and 2 mM DTT]. After 10 min incubation at 30‡C the
reaction was stopped by spotting 75% of the reaction mix onto pre-
labelled P81 phosphocellulose paper. The paper was washed repeat-
edly with 75 mM phosphoric acid and then allowed to dry for 1 h. 32P
incorporation into the GSK3 substrate was quanti¢ed by scintillation
spectrometry of the immobilised peptide.
2.5. Aggregation studies
Platelet aggregation was determined by optical aggregometry
(Chronolog Corp., Havertown, PA, USA) at 37‡C and with constant
stirring.
3. Results
3.1. GSK3K and GSK3L are present in human platelets
Immunoblot analysis (Fig. 1) shows that both GSK3K and
GSK3L are present in human platelet cell lysates, migrating
on SDS^PAGE with apparent molecular masses of 51 and 46
kDa, respectively.
3.2. Collagen, convulxin and thrombin induce phosphorylation
of GSK3K/L
GSK3 activity is inhibited by phosphorylation of speci¢c
amino terminal serine residues, Ser21 on GSK3K and Ser9
on GSK3L [16,17]. The phosphorylation states of GSK3K
and GSK3L in resting and activated platelets were examined
by immunoblot analysis of platelet lysates employing a phos-
Fig. 1. GSK3K and GSK3L are present in platelets. Platelets pro-
teins were separated by SDS^PAGE, transferred to PVDF mem-
branes and immunoblotted using GSK3K-speci¢c (a) and GSKL-spe-
ci¢c (b) antibodies.
Fig. 2. Agonist-stimulated phosphorylation of GSK3K and GSK3L.
Washed, indomethacin- and EGTA-treated platelets were stimulated
for the times indicated with either (a) collagen (100 Wg/ml), (b) con-
vulxin (125 ng/ml) or (c) thrombin (1 U/ml). Samples were sepa-
rated by SDS^PAGE, transferred to PVDF membranes and probed
with phospho-speci¢c GSK3 antibody (Ser21, GSK3K ; Ser9,
GSK3L). Data shown are representative of three separate experi-
ments.
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pho-speci¢c antibody that recognises the phosphorylated
forms of both Ser21 of GSKK and Ser9 on GSKL. GSK3L
was phosphorylated in resting platelets (Fig. 2). Stimulation
of platelets with collagen, convulxin or thrombin resulted in a
time- and concentration-dependent (data not shown) increase
in the levels of phosphorylation of both GSKK and GSKL
(Fig. 2). Increases in phosphorylation levels were rapid and
detectable within 20 s of stimulation. They continued to rise
up to 5 min of stimulation and thereafter declined over a
period of 1 h. Similar levels of GSK3 phosphorylation were
observed in samples where platelets were allowed to aggregate
through the omission of EGTA (data not shown).
Phosphorylation of GSK3K on Ser21 and GSK3L on Ser9
have been shown to be catalysed by a number of kinases,
including PKB, that are dependent on PI3K activation [18].
Indeed, the kinetic pro¢le of phosphorylation shown in Fig. 2
mirrors that observed for PKB phosphorylation in platelets
stimulated with collagen, convulxin and thrombin at the con-
centrations shown [10]. In order to verify that a PI3K-depen-
dent pathway was involved in the phosphorylation of GSK3
in activated platelets, structurally unrelated PI3K inhibitors,
LY294002 and wortmannin, were used [19,20]. Platelets were
pre-incubated with various concentrations of either inhibitor
and then stimulated with collagen, convulxin or thrombin.
Both PI3K inhibitors decreased substantially the phosphory-
lation of Ser9 on GSK3L, while inhibiting completely the de-
tectable phosphorylation of Ser21 on GSK3K, in response to
collagen, convulxin, and thrombin (Fig. 3). The levels of in-
hibition of GSK3 phosphorylation are similar to our reported
levels of inhibition of PKB Ser473 and Thr308 phosphorylation
at these concentrations of agonists and inhibitors [10]. This
supports the notion that GSK3 may be a target of PKB in
stimulated platelets.
3.3. GSK3 activity is regulated by stimulation of platelets
In vitro kinase assays were performed to determine whether
the activity of GSK3 might be regulated during platelet acti-
vation. Resting and stimulated platelets were assayed for
GSK3 activity either in the presence or absence of lithium
chloride (50 mM). Lithium inhibits GSK3 speci¢cally [20]
and, combined with the use of a speci¢c primed phosphopep-
tide substrate, was used to distinguish and correct for non-
speci¢c kinase activity present in the assays. Fig. 4 shows that
the activity of GSK3 is inhibited signi¢cantly following stim-
ulation of platelets with convulxin or thrombin. GSK3 activ-
ity was reduced to approximately 50% of basal levels follow-
ing platelet stimulation, which is similar to reports of GSK3
inhibition by other agonists [21]. This reduction in activity
was rescued by pre-incubating platelets with LY294002 (50
WM), con¢rming that GSK3 activity is regulated in a PI3K-
dependent manner.
3.4. Selective inhibitors of GSK3 inhibit platelet aggregation
Platelets were incubated with lithium chloride before stim-
ulation with collagen (0.5Wg/ml). Lithium was found to cause
a concentration-dependent inhibition of platelet aggregation
(Fig. 5a), with complete inhibition at a concentration of 50
mM, where platelet GSK3 activity was found to be inhibited
completely (data not shown). Although a recognised inhibitor
of GSK3, lithium has been reported to a¡ect the activity of
other signalling enzymes. Platelets were therefore incubated
with two structurally distinct selective GSK3 inhibitors,
SB415286 and TDZD-8 [22,23], and the e¡ect on platelet ag-
gregation in response to collagen (0.5 Wg/ml) and thrombin
(0.05 U/ml) determined. Using concentrations of these inhib-
itors that have previously been shown to reduce GSK3 activ-
ity in whole cells [22,23], concentration-dependent inhibition
of platelet aggregation in response to collagen and thrombin
(Fig. 5b and data not shown) was observed. Platelet GSK3
Fig. 3. Phosphorylation of platelet GSK3 is dependent on PI3K.
Washed, indomethacin- and EGTA-treated platelets were incubated
with varying concentrations of LY294002 or wortmannin, for 15
min prior to stimulation with collagen (Coll, 100 Wg/ml), convulxin
(Cvx, 125 ng/ml) or thrombin (Thr, 0.1 U/ml). Samples were sepa-
rated by SDS^PAGE and immunoblotted to detect phospho-
GSK3K/L. Results are representative of three separate experiments.
Fig. 4. GSK3 is inhibited on platelet activation. Platelets were
stimulated with convulxin (Cvx, 125 ng/ml) or thrombin (Thr, 0.1
U/ml) for 5 min, either in the presence or absence of LY294002
(LY, 50 WM), and then lysed. GSK3 kinase assays were performed
as described. Lithium-inhibitable GSK3 activity is expressed as a
percentage of activity in unstimulated platelets. Results represent
meanTS.D. (n=3). Student’s t test was used in comparison of con-
vulxin- and thrombin-stimulated samples with GSK3 activity in
basal cells to determine statistical signi¢cance (*P6 0.01).
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activity was measured following incubation with TDZD-8 and
SB415286 and representative concentration^inhibition rela-
tionships are shown in Fig. 5c. The pro¢le of GSK3 inhibition
with TDZD-8 and SB415286 correlated with the pro¢le of
inhibition of platelet aggregation, accounting for a degree of
donor variability that is typical in aggregation responses to
collagen.
4. Discussion
PI3Ks play a critical role in signalling mechanisms that
underlie the regulation of platelet function [9], although little
is known of the downstream signalling in these cells. We have
recently shown that PKB, a key downstream e¡ector of PI3K,
is regulated in collagen-stimulated platelets and may play a
Fig. 5. Selective inhibitors of GSK3 inhibit platelet aggregation. a: Washed platelets were incubated with the indicated concentrations of lith-
ium chloride for 2 min before stimulation of platelet aggregation with collagen (0.5 Wg/ml). b: Washed platelets were incubated with DMSO
alone or GSK3 inhibitors TDZD-8 and SB415286 at the concentrations shown for 15 min prior to stimulation with collagen (0.5 Wg/ml). Ag-
gregation was monitored by turbidometric aggregometry at 37‡C under stirring conditions for 90 s. Traces are representative of three separate
experiments. c: GSK3 activity in platelet lysates was determined following incubation of platelets with TDZD-8 and SB415286 at the concen-
trations shown. Results are expressed as % basal, lithium-inhibitable GSK3 activity.
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role in the regulation of platelet function [10]. Stimulation of
platelets with thrombin and TPO also cause PKB phosphor-
ylation and activation, although ADP and platelet activating
factor do not [10,11]. Here we report that GSK3K and
GSK3L, known PKB targets in other cell systems, are present
in human platelets, are regulated following platelet activation,
and through inhibitor studies implicate GSK3 in the regula-
tion of platelet function. GSK3 is widely expressed, although
it has not been previously shown to be present in platelets. It
is linked with a variety of cellular functions including regula-
tion of metabolism, the regulation of the transcription factors
c-jun, c-myc and c-myb, and eukaryotic initiation factor 2B
[24,25], the negative regulation of Wnt signalling [21] and
modulation of the microtubule-associated protein tau [26].
We report that platelet GSK3K and GSK3L are phosphor-
ylated on their N-terminal regulatory sites in a time- and con-
centration-dependent manner following stimulation with col-
lagen, convulxin or thrombin. Of the two isoforms, the
phosphorylation of GSK3L was more prominent, but this
may be a re£ection of di¡erential expression levels between
the isoforms in platelets, or di¡erential antibody binding
properties to the two serine phosphorylated isoforms.
Several kinases can phosphorylate GSK3K on Ser21 and
GSK3L on Ser9, including PKB [18]. Regulation of PKB in
platelets is dependent on the 3P phosphorylated phosphoinosi-
tide products of PI3K. Fig. 3 shows that incubation of plate-
lets with either LY294002 or wortmannin prior to platelet
stimulation with collagen, convulxin or thrombin reduced or
abolished GSK3 phosphorylation. However, higher concen-
trations of thrombin were able to overcome the e¡ects of
both inhibitors indicating the presence of a PI3K-independent
pathway. Indeed, thrombin-stimulated PKB regulation has
been previously reported to involve both PI3K-dependent
and PI3K-independent mechanisms [11].
Phosphorylation of GSK3K on Ser21 and GSK3L on Ser9
has been shown to result in a decrease in GSK3 activity
[16,17]. In the present study the stimulation of GPVI and
thrombin receptors on platelets resulted in attenuation of
GSK3 activity, falling to 50% of basal levels (Fig. 4). This
is similar in magnitude to the reduction in GSK3 activity
reported for insulin [21]. Pre-incubation of the samples with
LY294002 rescued the agonist-induced decrease in GSK3 ac-
tivity, con¢rming a role for PI3K.
To begin to examine the role of GSK3 in platelet function,
the e¡ects of three structurally distinct GSK3 inhibitors, lith-
ium, TDZD-8 and SB415286 [22,23], were explored. Each of
these inhibitors caused a concentration-dependent attenuation
of platelet aggregation in response to collagen (Fig. 5) and
thrombin (data not shown). These results were surprising
since GSK3 activity was reduced during platelet activation
and PI3K-dependent signalling has been shown to be required
for platelet aggregation. However, while each of these inhib-
itors is unlikely to be 100% selective for GSK3, the similar
e¡ects of three structurally distinct inhibitors are strongly
supportive of the role for GSK3 in the regulation of platelet
function. How might this apparent paradox be resolved? Giv-
en that GSK3 is active in unstimulated cells it is possible that
active GSK3 is necessary for priming platelets for aggrega-
tion. The signal for aggregation comes in part via the activa-
tion of the PI3K^PKB pathway but does not require GSK3.
However, activation of PI3K^PKB pathway results in inhibi-
tion of GSK3 activity, which may contribute to negative feed-
back regulation of platelet function. This latter point may be
considered analogous to the stimulation of inhibitory signal-
ling by platelet endothelial cell adhesion molecule-1 following
stimulation of platelets with collagen or thrombin [13].
As noted in [12] the full complement of in vivo GSK3 sub-
strates remains to be determined. Known substrates include
proteins involved in microtubule binding, protein sca¡olds,
cellular adhesion, metabolic enzymes, transcription factors
and components of cell cycle. While transcription factors
and cell cycle machinery are unlikely to be involved in plate-
lets, GSK3 substrates linked in other systems to regulation of
adhesion, cytoskeleton and metabolism might play a role. It is
possible that GSK3 is involved in the cytoskeletal reorganisa-
tion that platelets undergo when they are activated since both
aggregation and shape change are inhibited by TDZD-8 (Fig.
5b). Known GSK3 targets here include APC, MAP1B, L-cat-
enin, tau and presenilin-1. Of these proteins, all but tau have
been shown to be expressed in platelets [27,28]. Investigations
are currently underway to address these questions and to
identify and determine the physiologic function of substrates
of GSK3 in platelet function.
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